HK1206038A1 - Antigen binding protenins that bind dll-4 - Google Patents

Antigen binding protenins that bind dll-4 Download PDF

Info

Publication number
HK1206038A1
HK1206038A1 HK15106562.8A HK15106562A HK1206038A1 HK 1206038 A1 HK1206038 A1 HK 1206038A1 HK 15106562 A HK15106562 A HK 15106562A HK 1206038 A1 HK1206038 A1 HK 1206038A1
Authority
HK
Hong Kong
Prior art keywords
dll
antibodies
derivatives
polypeptides
methods
Prior art date
Application number
HK15106562.8A
Other languages
English (en)
Chinese (zh)
Inventor
Edwige Gros
Yanliang Zhang
Heyue Zhou
Randy GASTWIRT
Original Assignee
Sorrento Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics, Inc. filed Critical Sorrento Therapeutics, Inc.
Publication of HK1206038A1 publication Critical patent/HK1206038A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15106562.8A 2012-05-31 2013-05-28 Antigen binding protenins that bind dll-4 HK1206038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654019P 2012-05-31 2012-05-31
US61/654,019 2012-05-31
PCT/US2013/042912 WO2014062245A2 (en) 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4

Publications (1)

Publication Number Publication Date
HK1206038A1 true HK1206038A1 (en) 2015-12-31

Family

ID=49670535

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106562.8A HK1206038A1 (en) 2012-05-31 2013-05-28 Antigen binding protenins that bind dll-4

Country Status (7)

Country Link
US (2) US10174107B2 (https=)
EP (1) EP2855523A4 (https=)
JP (1) JP2015520172A (https=)
CN (1) CN104603151A (https=)
CA (1) CA2874979A1 (https=)
HK (1) HK1206038A1 (https=)
WO (1) WO2014062245A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20070244709A1 (en) * 2006-04-17 2007-10-18 Earthworks Systems, Llc Methods of producing and recycling plastic cards
KR20090027227A (ko) * 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
RU2581962C2 (ru) * 2008-09-19 2016-04-20 Медиммун Ллк Нацеленные средства связывания, направленные на dll4, и их применение
WO2011025964A2 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質

Also Published As

Publication number Publication date
WO2014062245A3 (en) 2014-10-09
CA2874979A1 (en) 2014-04-24
EP2855523A4 (en) 2016-02-17
US20130323248A1 (en) 2013-12-05
JP2015520172A (ja) 2015-07-16
US10717779B2 (en) 2020-07-21
WO2014062245A2 (en) 2014-04-24
EP2855523A2 (en) 2015-04-08
US10174107B2 (en) 2019-01-08
US20190169282A1 (en) 2019-06-06
CN104603151A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
HK1204557A1 (en) Antigen binding proteins that bind pd-l1
HK1221964A1 (zh) 与pd-1结合的抗原结合蛋白
HK1208181A1 (en) Antigen binding proteins that bind c-met
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
HK1214283A1 (zh) 與erbb3結合的抗原結合蛋白
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
HK1206038A1 (en) Antigen binding protenins that bind dll-4
WO2013173761A3 (en) St2 antigen binding proteins
WO2017015560A3 (en) Antibody therapeutics that bind lag3
WO2009155180A8 (en) Antibodies to il-6 and their uses
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
WO2014089335A3 (en) Bcma antigen binding proteins
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2009151717A3 (en) Bcr-complex-specific antibodies and methods of using same
WO2013043933A3 (en) Cd27l antigen binding proteins
HK1208474A1 (en) Antigen binding proteins that bind egfr
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2013191982A3 (en) Antigen binding proteins that bind igf1r
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
HK1214167A1 (zh) 與aip2結合的抗感染結合蛋白